Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®.

Xeglyze is a patent protected, single topical 10-minute application prescription product approved by the FDA and ready for market with manufacturing and supply chain through to finished product all in place and ready for launch.

A recent independent, peer-reviewed article in the Annals of Pharmacotherapy stated:

“The FDA approval of abametapir (Xeglyze) is an important development in the treatment of head lice infestations. It is the first pediculicide to inhibit metalloproteinases and exert substantial direct ovicidal and lousicidal activity, preventing the need for a second application. With an efficacy of 81% and a minor adverse effect profile, abametapir presents an effective new, user-friendly, and sustainable treatment option for head lice infestations.”

Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The product has an excellent safety profile. No nit-combing is required.

The product contains abametapir, an NCE with a novel mechanism of action with a low chance of resistance occurring due to its action on multiple pathways. Abametapir inhibits metalloproteinases that have a role in physiological process critical to egg development and survival of lice. Abametapir has the potential to be developed for further applications including Scabies with IP that lasts until December 2034.

Xeglyze® is a cosmetically pleasant lotion formulation with sufficient volume in each bottle to treat either short or long hair from a single prescription.

Sage is seeking an aquirer for Xeglyze and will be pleased to arrange a confidential call for discussion with the Hatchtech management team. Alternatively please contact Bill Mason or Wayne Pambianchi to arrange an informal discussion.